The SBS Blog – Welcome our new Chief Investigator!

/0 Comments/in , , , , /by

Please join us in welcoming Dr Sarah Gregory to the SBS Team as IONA National Coordinator! Read more about what she brings to Scottish Brain Sciences…

Read more

The SBS Blog – Welcome our new Senior Clinical Investigator!

/0 Comments/in , , , /by

We are thrilled to be able to welcome Dr Clara Russell to the SBS Team as Senior Clinical Investigator! Read more about what she brings to Scottish Brain Sciences…

Read more

Partnership seeks early Alzheimer’s blood test

/0 Comments/in , , /by

An agreement between Scottish Brain Sciences and a global leader in precision diagnostics is aiming to transform the ability of clinicians to identify the very earliest signs of Alzheimer’s Disease – long before symptoms can be seen.

Read more

Donanemab marks start of “new story” in Alzheimer’s research

/0 Comments/in , , , /by

Professor Craig Ritchie has told an international Alzheimer’s conference that phase 3 clinical trial results for donanemab, the antibody drug designed to target and clear the amyloid plaques considered key to progression of Alzheimer’s disease, reveal the drug’s “profound” clinical effect. 

Read more

Chief Scientist calls for more research volunteers

/0 Comments/in , , , /by

With the publication of Scotland’s new dementia strategy, the government’s Chief Scientist for Health, Professor Anna Dominiczack says it is now an important time to help make life-changing discoveries – encouraging Scots to volunteer for research into progressive brain conditions.

Read more

The SBS Blog – June 2023 Recap

/0 Comments/in , , , /by

With visits to both Boston, Massachusetts for the BIO Convention, as well as San Francisco, California, for an exciting Life Sciences reception, June 2023 was a big month for Scottish Brain Sciences. And one that also promised big things on the horizon!

Read more

Edinburgh team show how Alzheimer’s spreads

/0 Comments/in /by

New insights from research led by the University of Edinburgh reveal that the structures sending neurological signals and supporting normal brain function also enable the build-up of toxic proteins linked to Alzheimer’s disease – a finding which they say could prove vital in the search for therapies for slowing the progression of Alzheimer’s disease.

Read more

Pharma companies collaborate on early Alzheimer’s diagnoses

/0 Comments/in , /by

Roche has announced its collaboration with its counterpart Eli Lilly to try to achieve early diagnosis of Alzheimer’s disease using the diagnostic Elecsys Amyloid Plasma Panel – testing blood plasma for key Alzheimer’s disease markers.

Read more

Redefining clinical meaningfulness

/in , /by

A World Dementia Council Summit will this week (Monday) discuss how teams conducting clinical research into Alzheimer’s disease and wider dementia can measure what matters when some interventions clearly benefit patients but may not deliver the dramatic improvements needed to meet current definitions of effectiveness.

Read more

Dementia: A treatable condition of midlife

/in , , /by

One of the world’s foremost researchers into Alzheimer’s Disease and the wider diagnosis and treatment of dementia says, for the last century, investigations into these conditions have been focusing on the wrong place.

Read more